Panax Ginseng

Cancer

M.D. Anderson Cancer CenterPhase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 95/ 100

Competitive context

1411 Active assets in the Cancer cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Panax Ginseng is also rated in:

tardive dyskinesiaDormant

CCC

Indicative ·

52 / 100

schizoaffective disorderDormant

CCC

Indicative ·

48 / 100

Alzheimer diseaseDormant

CC

Indicative ·

46 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.